We previously found that a peptide derived from the tumor-associated type III-A2 domain of the tenascin-C molecule, termed TNIIIA2, is capable of inducing conformational change in β1-integrins that are necessary for its functional activation [11,12]. The gene discussed is TNC; the disease is neoplasm.